Roche to launch another Elevidys trial, hoping to win E.U. approval

Andrew Joseph covers well being, medication, and the biopharma trade in Europe. You may attain Andrew on Sign at drewqjoseph.71.

In an try and win European approval for the controversial medication, Roche stated Thursday it will run one other trial of the Duchenne muscular dystrophy gene remedy Elevidys. 

The Swiss firm’s transfer comes after European regulators final yr gave a damaging assessment to the remedy, saying it had did not exhibit long-term advantages for sufferers with the degenerative muscle situation. Roche has rights to the remedy outdoors the U.S., the place it’s marketed by its developer, Sarepta Therapeutics.

Roche stated the Section 3 trial will generate the kind of proof that would result in a resubmission with European officers and to functions with regulatory businesses in different components of the world. The examine will consider the security and efficacy of Elevidys versus placebo over 72 weeks in roughly 100 boys on the early levels of the illness.